• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, May 21, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Scientists discover critical anti-viral role of biological molecule

Bioengineer by Bioengineer
January 26, 2017
in Science News
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: Lisa Brown.

Scientists have discovered that a biological molecule important in cell growth (STAT3) is also critical in protecting us against infection – so much so that we would be unable to fight the common flu virus without it. Their discovery could pave the way to the development of new therapeutics charged with restoring our natural immunity to a whole spectrum of viruses that have evolved 'roadblocks' to the immune response.

The team behind the work was led by Assistant Professor in Immunology at Trinity College Dublin, Dr Nigel Stevenson. The findings have recently been published in the journal Cellular and Molecular Life Sciences CMLS – a PDF copy is available on request.

In a world of newly emerging viral infections such as SARS, ZIKA and Ebola, the importance of understanding how viruses target our immune system, and the need to develop new therapies to cure and protect us, has never been greater.

During any viral infection our cells produce an immune molecule called Interferon, which essentially 'interferes' with the battle plans of attacking viruses — preventing them from replicating in our bodies. When our cells are stimulated by Interferon a cascade of molecules within our cells is activated like a series of dominos. When the final one falls, the cell should be able to clear the viral infection. This cascade of molecules is termed a signalling pathway as it passes the 'danger signal' of viral infection through the cell.

The Interferon signalling pathway initiates the production of several hundred immune molecules that act to destroy viruses and amplify our immune response against them. However, as we know, many viruses are not cleared by our natural immune response and can often cause serious illness. Immunologists from Trinity, wondering how viruses suppress the immune response, have discovered that they have evolved numerous methods to inhibit these signalling pathways and thus block responses to Interferon.

Dr Stevenson said: "We thought that since the Interferon signalling pathway enhances the immune response against viruses so effectively, viruses might have evolved means to block it – such a reality would explain why several viruses are so troublesome to defeat."

Indeed, over the past few years, Dr Stevenson and his team had discovered that Hepatitis C Virus (HCV) and Respiratory Syncytial Virus (RSV), among others, specifically target the Interferon signalling pathway which helps them avoid being naturally cured by our immune systems.

Scientists had, until now, believed they fully understood how the Interferon signalling pathway worked, but by using a series of viral infections and cutting-edge molecular techniques, Dr Stevenson's team discovered a new anti-viral role for STAT3.

Dr Stevenson said: "For decades we have known that STAT3 is essential for healthy cell growth, but our new revelation identifies it for the first time as an essential anti-viral component in the Interferon signalling pathway. In fact, we found that without STAT3, cells cannot fight the common Flu virus or the Pox vaccinia virus."

"Of course a major goal of our ongoing work is to find solutions to the real-world problems faced by the thousands of people who cannot clear certain viruses after they have been infected. This discovery opens the door to new therapeutic options, which, we hope, will be able to help people restore their natural immunity against a host of problematic viruses."

###

Media Contact

Thomas Deane
[email protected]
353-189-64685
@tcddublin

http://www.tcd.ie/

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

NutriGrow Delphi Sets Standards for Preterm Nutrition Reporting — Technology and Engineering

NutriGrow Delphi Sets Standards for Preterm Nutrition Reporting

May 21, 2026

Critical Path Institute Unveils New Coalition to Propel Human-Relevant Drug Development Tools

May 21, 2026

Critical Path Institute Grants $249,719 to Odylia Therapeutics to Propel Gene Therapy for USH1C-Related Vision Loss

May 21, 2026

New Breakthrough Enables the Body to Combat Entire Families of Viruses

May 21, 2026
Please login to join discussion

POPULAR NEWS

  • blank

    New Study Reveals Plants Can Detect the Sound of Rain

    733 shares
    Share 292 Tweet 183
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    302 shares
    Share 121 Tweet 76
  • Research Indicates Potential Connection Between Prenatal Medication Exposure and Elevated Autism Risk

    846 shares
    Share 338 Tweet 212
  • Breastmilk Balances E. coli and Beneficial Bacteria in Infant Gut Microbiomes

    58 shares
    Share 23 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

NutriGrow Delphi Sets Standards for Preterm Nutrition Reporting

Critical Path Institute Unveils New Coalition to Propel Human-Relevant Drug Development Tools

Critical Path Institute Grants $249,719 to Odylia Therapeutics to Propel Gene Therapy for USH1C-Related Vision Loss

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 82 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.